# A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

> **NCT03311854** · PHASE2 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 14 (actual)

## Conditions studied

- Macrophage Activation Syndrome
- Lymphohistiocytosis, Hemophagocytic
- Arthritis, Juvenile
- Adult Onset Still Disease

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT03311854
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2020-05-19
- **Final completion:** 2020-05-19
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311854, "A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03311854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*